{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:05:16Z","timestamp":1793387116181,"version":"4.5.0"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T00:00:00Z","timestamp":1641945600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ebiom.2022.103840","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T05:39:01Z","timestamp":1643780341000},"page":"103840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"special_numbering":"C","title":["Immune checkpoint blockade in HIV"],"prefix":"10.1016","volume":"76","author":[{"given":"Celine","family":"Gubser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon R.","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ebiom.2022.103840_bib0001","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.chom.2020.03.014","article-title":"The biology of the HIV-1 latent reservoir and implications for cure strategies","volume":"27","author":"Cohn","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"3","key":"10.1016\/j.ebiom.2022.103840_bib0002","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.immuni.2007.08.010","article-title":"Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy","volume":"27","author":"Deeks","year":"2007","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.ebiom.2022.103840_bib0003","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/ni1515","article-title":"Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction","volume":"8","author":"Kaufmann","year":"2007","journal-title":"Nat Immunol"},{"issue":"7109","key":"10.1016\/j.ebiom.2022.103840_bib0004","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.ebiom.2022.103840_bib0005","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/nm1482","article-title":"Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction","volume":"12","author":"Trautmann","year":"2006","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ebiom.2022.103840_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005349","article-title":"TIGIT marks exhausted T cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV infection","volume":"12","author":"Chew","year":"2016","journal-title":"PLoS Pathog"},{"issue":"12","key":"10.1016\/j.ebiom.2022.103840_bib0007","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1097\/QAD.0000000000000314","article-title":"Programmed death-1 expression on CD4(+) and CD8(+) T cells in treated and untreated HIV disease","volume":"28","author":"Cockerham","year":"2014","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.ebiom.2022.103840_bib0008","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/QAD.0000000000002406","article-title":"T cells with high PD-1 expression are associated with lower HIV-specific immune responses despite long-term antiretroviral therapy","volume":"34","author":"Macatangay","year":"2020","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.ebiom.2022.103840_bib0009","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.immuni.2016.04.022","article-title":"Costimulatory and coinhibitory receptor pathways in infectious disease","volume":"44","author":"Attanasio","year":"2016","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.ebiom.2022.103840_bib0010","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"7652","key":"10.1016\/j.ebiom.2022.103840_bib0011","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ebiom.2022.103840_bib0012","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-021-01056-8","article-title":"Next generation of immune checkpoint inhibitors and beyond","volume":"14","author":"Marin-Acevedo","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.ebiom.2022.103840_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005761","article-title":"CD4+ T cells expressing PD-1, TIGIT and LAG-3 contribute to HIV persistence during ART","volume":"12","author":"Fromentin","year":"2016","journal-title":"PLoS Pathog"},{"issue":"8","key":"10.1016\/j.ebiom.2022.103840_bib0014","first-page":"893","article-title":"HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation","volume":"15","author":"Chomont","year":"2009","journal-title":"NatMed"},{"issue":"7","key":"10.1016\/j.ebiom.2022.103840_bib0015","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nm.4113","article-title":"PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals","volume":"22","author":"Banga","year":"2016","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.ebiom.2022.103840_bib0016","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1097\/QAD.0000000000001849","article-title":"Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency","volume":"32","author":"Evans","year":"2018","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.ebiom.2022.103840_bib0017","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/eji.201646875","article-title":"Immune checkpoints and their inhibition in cancer and infectious diseases","volume":"47","author":"Dyck","year":"2017","journal-title":"Eur J Immunol"},{"issue":"3","key":"10.1016\/j.ebiom.2022.103840_bib0018","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.ebiom.2022.103840_bib0019","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in Melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.ebiom.2022.103840_bib0020","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.immuni.2016.07.021","article-title":"T cell factor 1-expressing memory-like CD8(+) T cells sustain the immune response to chronic viral infections","volume":"45","author":"Utzschneider","year":"2016","journal-title":"Immunity"},{"issue":"7620","key":"10.1016\/j.ebiom.2022.103840_bib0021","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.ebiom.2022.103840_bib0022","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ni.3543","article-title":"CXCR5(+) follicular cytotoxic T cells control viral infection in B cell follicles","volume":"17","author":"Leong","year":"2016","journal-title":"Nat Immunol"},{"issue":"2","key":"10.1016\/j.ebiom.2022.103840_bib0023","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41577-019-0223-7","article-title":"Precursor exhausted T cells: key to successful immunotherapy?","volume":"20","author":"Kallies","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.ebiom.2022.103840_bib0024","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.immuni.2010.08.002","article-title":"Differentiation and persistence of memory CD8(+) T cells depend on T cell factor 1","volume":"33","author":"Zhou","year":"2010","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.ebiom.2022.103840_bib0025","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.ebiom.2022.103840_bib0026","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2018.11.043","article-title":"Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma","volume":"176","author":"Li","year":"2019","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ebiom.2022.103840_bib0027","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.immuni.2018.11.014","article-title":"Checkpoint blockade immunotherapy induces dynamic changes in PD-1(-)CD8(+) tumor-infiltrating T cells","volume":"50","author":"Kurtulus","year":"2019","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.ebiom.2022.103840_bib0028","doi-asserted-by":"crossref","first-page":"e136648","DOI":"10.1172\/jci.insight.136648","article-title":"TCF-1 regulates HIV-specific CD8+ T cell expansion capacity","volume":"6","author":"Rutishauser","year":"2021","journal-title":"JCI Insight"},{"issue":"8","key":"10.1016\/j.ebiom.2022.103840_bib0029","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/nm.2422","article-title":"Protective HIV-specific CD8+ T cells evade Treg cell suppression","volume":"17","author":"Elahi","year":"2011","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.ebiom.2022.103840_bib0030","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.4049\/jimmunol.179.3.1979","article-title":"Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T cell dysfunction","volume":"179","author":"D'Souza","year":"2007","journal-title":"J Immunol"},{"issue":"23","key":"10.1016\/j.ebiom.2022.103840_bib0031","doi-asserted-by":"crossref","first-page":"11536","DOI":"10.1128\/JVI.00485-08","article-title":"Human immunodeficiency virus type 1 Nef induces programmed death 1 expression through a p38 mitogen-activated protein kinase-dependent mechanism","volume":"82","author":"Muthumani","year":"2008","journal-title":"J Virol"},{"issue":"18","key":"10.1016\/j.ebiom.2022.103840_bib0032","doi-asserted-by":"crossref","first-page":"e122940","DOI":"10.1172\/jci.insight.122940","article-title":"Combination anti-PD-1 and antiretroviral therapy provides therapeutic benefit against SIV","volume":"3","author":"Mylvaganam","year":"2018","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.ebiom.2022.103840_bib0033","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.4049\/jimmunol.1901191","article-title":"Combination immune checkpoint blockade to reverse HIV latency","volume":"204","author":"Van der Sluis","year":"2020","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.ebiom.2022.103840_bib0034","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41467-019-08798-7","article-title":"PD-1 blockade potentiates HIV latency reversal ex vivo in CD4(+) T cells from ART-suppressed individuals","volume":"10","author":"Fromentin","year":"2019","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.ebiom.2022.103840_bib0035","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01163-19","article-title":"PD-1 blockade and TLR7 activation lack therapeutic benefit in chronic simian immunodeficiency virus-infected macaques on antiretroviral therapy","volume":"63","author":"Bekerman","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ebiom.2022.103840_bib0036","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.3389\/fimmu.2018.02415","article-title":"Immune protection of SIV challenge by PD-1 blockade during vaccination in rhesus monkeys","volume":"9","author":"Pan","year":"2018","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.ebiom.2022.103840_bib0037","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.it.2011.06.002","article-title":"Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation","volume":"32","author":"Wing","year":"2011","journal-title":"Trends Immunol"},{"issue":"4","key":"10.1016\/j.ebiom.2022.103840_bib0038","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.immuni.2017.09.018","article-title":"CTLA-4(+)PD-1(-) memory CD4(+) T cells critically contribute to viral persistence in antiretroviral therapy-suppressed, SIV-infected rhesus macaques","volume":"47","author":"McGary","year":"2017","journal-title":"Immunity"},{"issue":"Pt 6","key":"10.1016\/j.ebiom.2022.103840_bib0039","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1099\/vir.0.000065","article-title":"Nef promotes evasion of human immunodeficiency virus type 1-infected cells from the CTLA-4-mediated inhibition of T-cell activation","volume":"96","author":"El-Far","year":"2015","journal-title":"J Gen Virol"},{"issue":"8","key":"10.1016\/j.ebiom.2022.103840_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008696","article-title":"Selective upregulation of CTLA-4 on CD8+ T cells restricted by HLA-B*35Px renders them to an exhausted phenotype in HIV-1 infection","volume":"16","author":"Elahi","year":"2020","journal-title":"PLoS Pathog"},{"issue":"12","key":"10.1016\/j.ebiom.2022.103840_bib0041","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1182\/blood-2006-04-010637","article-title":"CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques","volume":"108","author":"Hryniewicz","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ebiom.2022.103840_bib0042","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.4049\/jimmunol.180.8.5439","article-title":"Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection","volume":"180","author":"Cecchinato","year":"2008","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.ebiom.2022.103840_bib0043","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41591-020-0782-y","article-title":"CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption","volume":"26","author":"Harper","year":"2020","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.ebiom.2022.103840_bib0044","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3390\/vaccines8020284","article-title":"CTLA-4 blockade, during HIV virus-like particles immunization, alters HIV-specific B-cell responses","volume":"8","author":"Lewis","year":"2020","journal-title":"Vaccines"},{"issue":"5","key":"10.1016\/j.ebiom.2022.103840_bib0045","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.ebiom.2022.103840_bib0046","doi-asserted-by":"crossref","first-page":"3873","DOI":"10.4049\/jimmunol.1402176","article-title":"The upregulation of LAG-3 on T cells defines a subpopulation with functional exhaustion and correlates with disease progression in HIV-infected subjects","volume":"194","author":"Tian","year":"2015","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.ebiom.2022.103840_bib0047","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005661","article-title":"Exhaustion of activated CD8 T cells predicts disease progression in primary HIV-1 infection","volume":"12","author":"Hoffmann","year":"2016","journal-title":"PLoS Pathog"},{"issue":"12","key":"10.1016\/j.ebiom.2022.103840_bib0048","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ni1271","article-title":"The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity","volume":"6","author":"Zhu","year":"2005","journal-title":"Nat Immunol"},{"issue":"12","key":"10.1016\/j.ebiom.2022.103840_bib0049","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1084\/jem.20081398","article-title":"TIM-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection","volume":"205","author":"Jones","year":"2008","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.ebiom.2022.103840_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101042","article-title":"The HIV-1 accessory protein Nef increases surface expression of the checkpoint receptor TIM-3 in infected CD4(+) T cells","volume":"297","author":"Jacob","year":"2021","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.ebiom.2022.103840_bib0051","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01999-19","article-title":"HIV-1 Vpu downregulates TIM-3 from the surface of infected CD4(+) T cells","volume":"94","author":"Pr\u00e9vost","year":"2020","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.ebiom.2022.103840_bib0052","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02214-20","article-title":"Effect of the use of Galectin-9 and blockade of TIM-3 receptor in the latent cellular reservoir of HIV-1","volume":"95","author":"Sanz","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.ebiom.2022.103840_bib0053","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3389\/fcimb.2020.00175","article-title":"TIGIT blockade: a multipronged approach to target the HIV reservoir","volume":"10","author":"Holder","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"issue":"3","key":"10.1016\/j.ebiom.2022.103840_bib0054","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.4049\/jimmunol.1003081","article-title":"Cutting edge: TIGIT has T cell-intrinsic inhibitory functions","volume":"186","author":"Joller","year":"2011","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.ebiom.2022.103840_bib0055","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/cdd.2012.141","article-title":"Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells","volume":"20","author":"Liu","year":"2013","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.ebiom.2022.103840_bib0056","doi-asserted-by":"crossref","first-page":"40354","DOI":"10.1038\/srep40354","article-title":"Perturbed CD8(+) T cell TIGIT\/CD226\/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals","volume":"7","author":"Tauriainen","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ebiom.2022.103840_bib0057","article-title":"Analysis of the characteristics of TIGIT-expressing CD3(-)CD56(+)NK cells in controlling different stages of HIV-1 infection","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.ebiom.2022.103840_bib0058","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review","volume":"5","author":"Cook","year":"2019","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.ebiom.2022.103840_bib0059","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer-a phase 1 study","volume":"5","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.ebiom.2022.103840_bib0060","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jamaoncol.2020.0465","article-title":"Assessment of the feasibility and safety of durvalumab for treatment of solid tumors in patients with HIV-1 infection: the phase 2 DURVAST study","volume":"6","author":"Gonzalez-Cao","year":"2020","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.ebiom.2022.103840_bib0061","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/QAD.0000000000000562","article-title":"Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma","volume":"29","author":"Wightman","year":"2015","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.ebiom.2022.103840_bib0062","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/annonc\/mdx696","article-title":"Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer","volume":"29","author":"Guihot","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ebiom.2022.103840_bib0063","series-title":"Pembrolizumab Induces HIV Latency Reversal in HIV+ Individuals on ART With Cancer","author":"Uldrick","year":"2019"},{"issue":"10","key":"10.1016\/j.ebiom.2022.103840_bib0064","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1093\/annonc\/mdy259","article-title":"Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection","volume":"29","author":"Scully","year":"2018","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ebiom.2022.103840_bib0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211112","article-title":"Blockade of the PD-1 axis alone is not sufficient to activate HIV-1 virion production from CD4+ T cells of individuals on suppressive ART","volume":"14","author":"Bui","year":"2019","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.ebiom.2022.103840_bib0066","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/QAD.0000000000002919","article-title":"The impact of immune checkpoint therapy on the latent reservoir in HIV infected individuals with cancer on antiretroviral therapy","volume":"35","author":"Lau","year":"2021","journal-title":"AIDS"},{"issue":"7","key":"10.1016\/j.ebiom.2022.103840_bib0067","doi-asserted-by":"crossref","first-page":"e1973","DOI":"10.1093\/cid\/ciaa1530","article-title":"Impact of anti-PD-1 and anti-CTLA-4 on the HIV reservoir in people living with HIV with cancer on antiretroviral therapy: the AIDS Malignancy Consortium-095 study","volume":"73","author":"Rasmussen","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.ebiom.2022.103840_bib0068","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1093\/infdis\/jix191","article-title":"Clinical trial of the anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy","volume":"215","author":"Gay","year":"2017","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.ebiom.2022.103840_bib0069","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.1097\/QAI.0000000000002716","article-title":"Suspected immune-related adverse events with an anti-PD-1 inhibitor in otherwise healthy people with HIV","volume":"87","author":"Gay","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"10.1016\/j.ebiom.2022.103840_bib0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198158","article-title":"An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients","volume":"13","author":"Colston","year":"2018","journal-title":"PLoS ONE"},{"issue":"16","key":"10.1016\/j.ebiom.2022.103840_bib0071","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ebiom.2022.103840_bib0072","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ebiom.2022.103840_bib0073","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.ebiom.2022.103840_bib0074","doi-asserted-by":"crossref","first-page":"950","DOI":"10.4049\/jimmunol.1401686","article-title":"Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo","volume":"194","author":"Das","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.ebiom.2022.103840_bib0075","article-title":"Combination immune checkpoint blockade enhances IL-2 and CD107a production from HIV-specific T cells ex vivo in people living with HIV on antiretroviral therapy","author":"Chiu","year":"2021","journal-title":"J Immunol"},{"key":"10.1016\/j.ebiom.2022.103840_bib0076","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.clim.2017.09.002","article-title":"Antibodies targeting BTLA or TIM-3 enhance HIV-1 specific T cell responses in combination with PD-1 blockade","volume":"183","author":"Grabmeier-Pfistershammer","year":"2017","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ebiom.2022.103840_bib0077","doi-asserted-by":"crossref","DOI":"10.1097\/QAI.0000000000002716","article-title":"Suspected immune-related adverse events with an anti-PD-1 inhibitor in healthy people with HIV","author":"Gay","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"10.1016\/j.ebiom.2022.103840_bib0078","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1093\/infdis\/jix191","article-title":"Clinical trial of the Anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy","volume":"215","author":"Gay","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ebiom.2022.103840_bib0079","article-title":"Resistance to immunotherapy in human malignancies: mechanisms, research progresses, challenges, and opportunities","author":"Bashash","year":"2021","journal-title":"J Cell Physiol"},{"issue":"12","key":"10.1016\/j.ebiom.2022.103840_bib0080","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1158\/2326-6066.CIR-15-0097","article-title":"Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors","volume":"3","author":"Thommen","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"10.1016\/j.ebiom.2022.103840_bib0081","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.ebiom.2022.103840_bib0082","doi-asserted-by":"crossref","first-page":"734","DOI":"10.3389\/fimmu.2018.00734","article-title":"Regulatory T cells as potential targets for HIV cure research","volume":"9","author":"Kleinman","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2022.103840_bib0083","doi-asserted-by":"crossref","first-page":"25758","DOI":"10.1038\/srep25758","article-title":"Monoclonal regulatory T cells provide insights into T cell suppression","volume":"6","author":"Gubser","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ebiom.2022.103840_bib0084","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3389\/fimmu.2019.00292","article-title":"FcgammaR-Binding is an important functional attribute for immune checkpoint antibodies in cancer immunotherapy","volume":"10","author":"Chen","year":"2019","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.ebiom.2022.103840_bib0085","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ccell.2018.02.010","article-title":"Fc effector function contributes to the activity of human Anti-CTLA-4 antibodies","volume":"33","author":"Arce Vargas","year":"2018","journal-title":"Cancer Cell"},{"issue":"15","key":"10.1016\/j.ebiom.2022.103840_bib0086","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1073\/pnas.1801524115","article-title":"Anti-CTLA-4 therapy requires an Fc domain for efficacy","volume":"115","author":"Ingram","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.ebiom.2022.103840_bib0087","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41591-019-0420-8","article-title":"Rational design of anti-GITR-based combination immunotherapy","volume":"25","author":"Zappasodi","year":"2019","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ebiom.2022.103840_bib0088","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamaoncol.2020.7684","article-title":"Response rates to Anti-PD-1 immunotherapy in microsatellite-stable solid tumors with 10 or more mutations per megabase","volume":"7","author":"Valero","year":"2021","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.ebiom.2022.103840_bib0089","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/eji.200323382","article-title":"The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells","volume":"33","author":"Workman","year":"2003","journal-title":"Eur J Immunol"},{"issue":"9","key":"10.1016\/j.ebiom.2022.103840_bib0090","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.4049\/jimmunol.172.9.5450","article-title":"Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo","volume":"172","author":"Workman","year":"2004","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.ebiom.2022.103840_bib0091","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","article-title":"Role of LAG-3 in regulatory T cells","volume":"21","author":"Huang","year":"2004","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.ebiom.2022.103840_bib0092","doi-asserted-by":"crossref","first-page":"5916","DOI":"10.4049\/jimmunol.180.9.5916","article-title":"Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II","volume":"180","author":"Liang","year":"2008","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.ebiom.2022.103840_bib0093","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/ni.2376","article-title":"Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1","volume":"13","author":"Chiba","year":"2012","journal-title":"Nat Immunol"},{"issue":"7534","key":"10.1016\/j.ebiom.2022.103840_bib0094","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nature13848","article-title":"CEACAM1 regulates TIM-3-mediated tolerance and exhaustion","volume":"517","author":"Huang","year":"2015","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ebiom.2022.103840_bib0095","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/eji.201041136","article-title":"Vstm3 is a member of the CD28 family and an important modulator of T-cell function","volume":"41","author":"Levin","year":"2011","journal-title":"Eur J Immunol"},{"issue":"4","key":"10.1016\/j.ebiom.2022.103840_bib0096","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.immuni.2020.09.010","article-title":"CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8(+) T cells","volume":"53","author":"Braun","year":"2020","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.ebiom.2022.103840_bib0097","doi-asserted-by":"crossref","first-page":"531","DOI":"10.4049\/immunohorizons.1900087","article-title":"Galectin-9 expression defines a subpopulation of NK cells with impaired cytotoxic effector molecules but enhanced IFN-\u03b3 production, dichotomous to TIGIT, in HIV-1 infection","volume":"3","author":"Motamedi","year":"2019","journal-title":"Immunohorizons"},{"issue":"9","key":"10.1016\/j.ebiom.2022.103840_bib0098","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.4049\/jimmunol.1901481","article-title":"Galectin-9 and VISTA expression define terminally exhausted T cells in HIV-1 infection","volume":"204","author":"Shahbaz","year":"2020","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.ebiom.2022.103840_bib0099","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1089\/aid.2014.0004","article-title":"Galectin-9 is rapidly released during acute HIV-1 infection and remains sustained at high levels despite viral suppression even in elite controllers","volume":"30","author":"Tandon","year":"2014","journal-title":"AIDS Res Hum Retrovir"},{"issue":"8","key":"10.1016\/j.ebiom.2022.103840_bib0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001387","article-title":"Neutrophils promote T-cell activation through the regulated release of CD44-bound Galectin-9 from the cell surface during HIV infection","volume":"19","author":"Dunsmore","year":"2021","journal-title":"PLoS Biol"},{"issue":"7","key":"10.1016\/j.ebiom.2022.103840_bib0101","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nm.4113","article-title":"PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals","volume":"22","author":"Banga","year":"2016","journal-title":"Nat Med"},{"issue":"Pt 12","key":"10.1016\/j.ebiom.2022.103840_bib0102","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1099\/vir.0.055541-0","article-title":"The human immunodeficiency virus type 1 Vpr protein upregulates PVR via activation of the ATR-mediated DNA damage response pathway","volume":"94","author":"Vassena","year":"2013","journal-title":"J Gen Virol"},{"issue":"6","key":"10.1016\/j.ebiom.2022.103840_bib0103","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/QAD.0000000000002488","article-title":"TIGIT is upregulated by HIV-1 infection and marks a highly functional adaptive and mature subset of natural killer cells","volume":"34","author":"Vendrame","year":"2020","journal-title":"AIDS"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235239642200024X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235239642200024X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:16:48Z","timestamp":1762456608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235239642200024X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":103,"alternative-id":["S235239642200024X"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.103840","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint blockade in HIV","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.103840","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103840"}}